Avalanche Biotechnologies Inc. shares fell after a gene therapy trial for wet AMD showed patients still needed additional drug injections. The trial data indicated that patients treated with AVA-101 required fewer injections than the control group. Despite meeting safety goals, the trial did not meet high expectations, affecting the company's stock value.
documents/vol00010-efta01368453-pdf.pdf
{"title":"Avalanche Drops as Gene Therapy Trial Miss High Expectations","key_people":["Danielle Burger","Gbola Amusa","Thomas Chalberg"],"document_date":"2015-06-15","document_type":"media","key_locations":["New York","U.S."],"key_organizations":["Avalanche Biotechnologies Inc.","Roche Holding AG","Chardan Capital Markets","Regeneron Pharmaceuticals Inc."]}